The US Food and Drug Administration is eager to correct the “persistent misconception” that recommendations by its public advisory committees amount to final decisions or are somehow binding on the agency.
The agency says so, at some length, in its recent announcement of a 13 June “listening session” for stakeholders to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?